Ji-hao Zhou

P.R. China
Shenzhen, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

An individualized nomogram for predicting progression-free survival in systemic anaplastic large cell lymphoma: a multicenter, retrospective, and internally validated study.

An individualized nomogram for predicting progression-free survival in systemic anaplastic large cell lymphoma: a multicenter, retrospective, and internally validated study.

Journal: Hematology (Amsterdam, Netherlands)

Published: August 12, 2026

Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML.

Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML.

Journal: Cell metabolism

Published: August 05, 2026

A novel PML::RARA fusion in acute promyelocytic leukemia: a case report and literature review.

A novel PML::RARA fusion in acute promyelocytic leukemia: a case report and literature review.

Journal: Frontiers in oncology

Published: January 09, 2026

Epstein-barr virus-encoded small RNA incorporated prognostic model enables precision risk stratification and guides treatment decisions in peripheral t-cell lymphoma: a multicenter retrospective cohort.

Epstein-barr virus-encoded small RNA incorporated prognostic model enables precision risk stratification and guides treatment decisions in peripheral t-cell lymphoma: a multicenter retrospective cohort.

Journal: Annals of hematology

Published: August 24, 2025

Correction: EBV-positive diffuse large B cell lymphoma secondary to activated phosphoinositide 3 kinase δ syndrome type 1 (APDS1): a case report and literature review.

Correction: EBV-positive diffuse large B cell lymphoma secondary to activated phosphoinositide 3 kinase δ syndrome type 1 (APDS1): a case report and literature review.

Journal: Frontiers in immunology

Published: July 03, 2025

Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML.

Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML.

Journal: Cell metabolism

Published: April 24, 2025

EBV-positive diffuse large B cell lymphoma secondary to activated phosphoinositide 3 kinase δ syndrome type 1 (APDS1): a case report and literature review.

EBV-positive diffuse large B cell lymphoma secondary to activated phosphoinositide 3 kinase δ syndrome type 1 (APDS1): a case report and literature review.

Journal: Frontiers in immunology

Published: February 25, 2025

Real-world data on clinical outcomes and validation of prognostic models for angioimmunoblastic T-cell lymphoma: a multicentric retrospective study in Southern China.

Real-world data on clinical outcomes and validation of prognostic models for angioimmunoblastic T-cell lymphoma: a multicentric retrospective study in Southern China.

Journal: Frontiers in oncology

Published: February 20, 2025

A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential.

A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential.

Journal: Cell reports

Published: February 09, 2025

Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma.

Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphoma.

Journal: iScience

Published: July 05, 2023

Identification of FCER1G as a key gene in multiple myeloma based on weighted gene co-expression network analysis.

Identification of FCER1G as a key gene in multiple myeloma based on weighted gene co-expression network analysis.

Journal: Hematology (Amsterdam, Netherlands)

Published: May 12, 2023

Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.

Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.

Journal: Current medical science

Published: February 25, 2017

Showing 1-12 of 15

Last Updated: 09/26/2026